TY - JOUR T1 - Ocular toxicity and Hydroxychloroquine: A Rapid Meta-Analysis JF - medRxiv DO - 10.1101/2020.04.28.20083378 SP - 2020.04.28.20083378 AU - Matthew Michelson AU - Tiffany Chow AU - Neil Martin AU - Mike Ross AU - Amelia Tee AU - Steven Minton Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/12/2020.04.28.20083378.abstract N2 - Rapid access to evidence is crucial in times of evolving clinical crisis. To that end, we propose a novel mechanism to answer clinical queries: Rapid Meta-Analysis (RMA). Unlike traditional meta-analysis, RMA balances quick time-to-production with reasonable data quality assurances, leveraging Artificial Intelligence to strike this balance. This article presents an example RMA to a currently relevant clinical question: Is ocular toxicity and vision compromise a side effect with hydroxychloroquine therapy?As of this writing, hydroxychloroquine is a leading candidate in the treatment of COVID-19. By combining AI with human analysis, our RMA identified 11 studies looking at ocular toxicity as a side effect and estimated the incidence to be 3.4% (95% CI: 1.11-9.96%). The heterogeneity across the individual study findings was high, and interpretation of the result should take this into account. Importantly, this RMA, from search to screen to analysis, took less than 30 minutes to produce.Competing Interest StatementMatthew Michelson, Tiffany Chow, Mike Ross and Amelia Tee are employees of Evid Science, whose AI and data set were used in this publication.Funding StatementNo external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe include all of the data for the meta-analysis within a table in the paper for completeness and easy availability. ER -